ZA200807903B - Humanized monoclonal antibodies to hepatocyte growth factor - Google Patents

Humanized monoclonal antibodies to hepatocyte growth factor

Info

Publication number
ZA200807903B
ZA200807903B ZA200807903A ZA200807903A ZA200807903B ZA 200807903 B ZA200807903 B ZA 200807903B ZA 200807903 A ZA200807903 A ZA 200807903A ZA 200807903 A ZA200807903 A ZA 200807903A ZA 200807903 B ZA200807903 B ZA 200807903B
Authority
ZA
South Africa
Prior art keywords
growth factor
monoclonal antibodies
hepatocyte growth
humanized monoclonal
humanized
Prior art date
Application number
ZA200807903A
Other languages
English (en)
Inventor
Kyung Jin Kim
Lihong Wang
Hangil Park
Maximiliano Vasquez
Original Assignee
Galaxy Biotech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galaxy Biotech Llc filed Critical Galaxy Biotech Llc
Publication of ZA200807903B publication Critical patent/ZA200807903B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA200807903A 2006-04-01 2007-03-28 Humanized monoclonal antibodies to hepatocyte growth factor ZA200807903B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78824306P 2006-04-01 2006-04-01

Publications (1)

Publication Number Publication Date
ZA200807903B true ZA200807903B (en) 2010-03-31

Family

ID=38564195

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200807903A ZA200807903B (en) 2006-04-01 2007-03-28 Humanized monoclonal antibodies to hepatocyte growth factor

Country Status (26)

Country Link
US (3) US7632926B2 (fr)
EP (2) EP2476704A3 (fr)
JP (1) JP5312315B2 (fr)
KR (1) KR101516289B1 (fr)
CN (2) CN101415811B (fr)
AR (1) AR059922A1 (fr)
AU (1) AU2007233242B2 (fr)
BR (1) BRPI0709932A2 (fr)
CA (1) CA2645358C (fr)
CO (1) CO6140067A2 (fr)
CR (1) CR10308A (fr)
ES (1) ES2465668T3 (fr)
GE (1) GEP20125517B (fr)
HK (1) HK1121489A1 (fr)
IL (1) IL194221A (fr)
MA (1) MA30382B1 (fr)
MX (1) MX2008012619A (fr)
MY (1) MY145042A (fr)
NO (1) NO20084539L (fr)
NZ (1) NZ571132A (fr)
PE (1) PE20080008A1 (fr)
RU (1) RU2461570C2 (fr)
TW (1) TWI417300B (fr)
UA (1) UA94452C2 (fr)
WO (1) WO2007115049A2 (fr)
ZA (1) ZA200807903B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
CN103880955A (zh) 2003-07-18 2014-06-25 安姆根有限公司 肝细胞生长因子的特异性结合物
BRPI0611009A2 (pt) * 2005-06-02 2010-08-10 Galaxy Biotech Llc usos de um anticorpo monoclonal (mab), e, de um anticorpo anti-hgf de neutralização
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
AR061170A1 (es) 2006-06-02 2008-08-06 Aveo Pharmaceuticals Inc Proteinas que se unen con el factor de crecimiento de hepatocitos (hgf)
BRPI0712222B1 (pt) 2006-06-02 2021-10-13 Aveo Pharmaceuticals, Inc. Proteína de ligação isolada que se liga ao fator de crescimento de hepatócito humano (hgf), seu uso e método de produção, ácido nucléico, vetor de expressão, célula hospedeira, e métodos para produzir um polipeptídeo que compreende uma região variável da cadeia pesada de imunoglobulina e para produzir um polipeptídeo que compreende uma região variável da cadeia leve de imunoglobulina
JP2009539403A (ja) 2006-06-13 2009-11-19 オンコメッド ファーマシューティカルズ インコーポレイテッド 癌を診断および処置するための組成物および方法
JP5618544B2 (ja) 2007-01-24 2014-11-05 オンコメッドファーマシューティカルズ インコーポレイテッド 癌の診断および処置のための組成物および方法
CN102014913A (zh) * 2008-03-06 2011-04-13 健泰科生物技术公司 C-met和egfr拮抗剂的联合疗法
WO2009125381A1 (fr) * 2008-04-10 2009-10-15 Objet Geometries Ltd. Système et procédé pour l’impression de modèles en trois dimensions
US20110217294A1 (en) * 2008-04-11 2011-09-08 Daniel Fults Combination of hgf inhibitor and hedgehog inhibitor to treat cancer
TW200948380A (en) * 2008-04-11 2009-12-01 Galaxy Biotech Llc Combination of HGF inhibitor and PTEN agonist to treat cancer
PE20091827A1 (es) * 2008-04-11 2009-11-20 Galaxy Biotech Llc Combinacion del inhibidor hgf y el inhibidor egf para el tratamiento del cancer
US20110104161A1 (en) * 2008-05-14 2011-05-05 Burgess Teresa L Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
WO2009148928A1 (fr) 2008-05-29 2009-12-10 Galaxy Biotech, Llc Anticorps monoclonaux dirigés contre un facteur de croissance fibroblastique basique
SI2307051T1 (sl) 2008-07-08 2015-04-30 Oncomed Pharmaceuticals, Inc. Notch-vezavna sredstva in antagonisti ter postopki njihove uporabe
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
EP3783024A1 (fr) 2008-11-07 2021-02-24 Galaxy Biotech, LLC Anticorps monoclonaux dirigés contre le récepteur 2 du facteur de croissance des fibroblastes
JPWO2010071208A1 (ja) 2008-12-19 2012-05-31 武田薬品工業株式会社 抗体の精製方法
WO2010119991A2 (fr) 2009-04-17 2010-10-21 Takeda Pharmaceutical Company Limited Nouveau procédé de traitement anticancéreux
AR078046A1 (es) * 2009-05-28 2011-10-12 Glaxo Group Ltd Proteinas de union a antigeno
WO2011088215A2 (fr) * 2010-01-13 2011-07-21 Oncomed Pharmaceuticals, Inc. Agents de liaison notch1 et leurs procédés d'utilisation
EP2545077B1 (fr) 2010-03-10 2018-10-31 Genmab A/S Anticorps monoclonaux contre c-met
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
US20140057908A1 (en) 2010-09-27 2014-02-27 Exelixis, Inc. Method of Treating Cancer
KR20130121886A (ko) * 2010-11-24 2013-11-06 글락소 그룹 리미티드 Ｈｇｆ를 표적으로 하는 다중특이적 항원 결합 단백질
CA2847245A1 (fr) 2011-09-09 2013-03-14 Amgen Inc. Utilisation de la proteine c-met pour predire l'efficacite d'anticorps anti-facteur de croissance des hepatocytes (« hgf ») chez des patients atteints d'un cancer de l'ƒsophage et de l'estomac
WO2013152252A1 (fr) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Polythérapie antinéoplasique
EP2873422A4 (fr) 2012-07-10 2015-12-30 Takeda Pharmaceutical Préparation pharmaceutique pour l'injection
EP2708556B1 (fr) 2012-09-12 2018-11-07 Samsung Electronics Co., Ltd Composition pharmaceutique à utiliser dans une thérapie combinée pour la prévention ou le traitement des maladies induites par c-met ou le facteur d'angiogénèse
US9062104B2 (en) 2013-03-14 2015-06-23 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
KR20150140685A (ko) * 2013-03-14 2015-12-16 앨더 바이오파마슈티컬즈, 인코포레이티드 Hgf에 대한 항체 및 이를 포함하는 조성물
US9732150B2 (en) 2013-03-14 2017-08-15 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
CN107002119A (zh) 2014-03-24 2017-08-01 豪夫迈·罗氏有限公司 使用c‑met拮抗剂的癌症治疗及前者与hgf表达的关联
MX2018005097A (es) 2015-10-30 2019-05-16 Galaxy Biotech Llc Anticuerpos altamente potentes que se unen a receptor de muerte 4 y receptor de muerte 5.
US10906987B2 (en) 2016-03-01 2021-02-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human poliovirus receptor (PVR)
EP4013869A1 (fr) 2019-08-12 2022-06-22 InteRNA Technologies B.V. Nouveaux traitements impliquant le miarn-193a
CA3167367A1 (fr) 2020-02-28 2021-09-02 Sanaz YAHYANEJAD Miarn-193a pour favoriser la mort cellulaire immunogene
CN113980129B (zh) * 2021-01-15 2023-07-28 东大生物技术(苏州)有限公司 一组il-11单克隆抗体及其医药用途

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2564486B2 (ja) 1986-07-14 1996-12-18 修治 橋本 肝細胞増殖因子
WO1988007089A1 (fr) 1987-03-18 1988-09-22 Medical Research Council Anticorps alteres
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1690935A3 (fr) 1990-01-12 2008-07-30 Abgenix, Inc. Génération d'anticorps xenogéniques
GB9009548D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
WO1993012227A1 (fr) 1991-12-17 1993-06-24 Genpharm International, Inc. Animaux transgeniques non humains capables de produire des anticorps heterologues
DK0590058T3 (da) * 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
US6498144B1 (en) 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5837676A (en) 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US5707624A (en) 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5646036A (en) 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
CA2258153C (fr) 1996-07-03 2004-08-17 Genentech, Inc. Agonistes de recepteur du facteur de croissance des hepatocytes et utilisation desdits agonistes
EP1183275B1 (fr) * 1999-05-17 2006-08-09 Avi Biopharma, Inc. Anticorps specifique pour la gonadotropine chorionique humaine et leur utilisation en therapie et diagnostic
WO2001034650A1 (fr) 1999-11-09 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Heatlh And Human Services Combinaison d'anticorps monoclonaux hgf-sf
WO2003010282A2 (fr) 2001-07-26 2003-02-06 Eli Lilly And Company Anticorps vis-a-vis de l'interleukine 1 beta (il-1$g(b))
AU2002357388A1 (en) 2001-12-27 2003-07-24 The United States Of America, As Represented By The Department Of Veterans Affairs Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor
AU2003270118A1 (en) 2002-08-30 2004-03-19 F. Hoffmann-La Roche Ag Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma
AU2003900180A0 (en) * 2003-01-16 2003-01-30 Silverbrook Research Pty Ltd Method and apparatus (dam001)
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
US7220410B2 (en) * 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
PL1636593T3 (pl) 2003-06-06 2009-08-31 Genentech Inc Modulowanie oddziaływania pomiędzy łańcuchem beta HGF i c-met.
WO2005007193A2 (fr) 2003-07-07 2005-01-27 Vande Woude, George, F. Inhibition de l'angiogenese tumorale par combinaison de la thrombospondine-1 et des inhibiteurs du facteur de croissance endotheliale vasculaire
CN103880955A (zh) 2003-07-18 2014-06-25 安姆根有限公司 肝细胞生长因子的特异性结合物
EP1665241A1 (fr) 2003-09-18 2006-06-07 Koninklijke Philips Electronics N.V. Support d'information et systeme pour lire des donnees stockees sur un tel support
ES2925655T3 (es) 2003-09-26 2022-10-19 Exelixis Inc Moduladores c-Met y métodos de uso
KR100556660B1 (ko) 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
WO2005079489A2 (fr) * 2004-02-17 2005-09-01 Science & Technology Corporation @ Unm Procede pour traiter le cancer et identifier de nouveaux composes anticancereux
CA2572331A1 (fr) 2004-07-02 2006-02-09 Exelixis, Inc. Modulateurs de c-met et leur methode d'utilisation
BRPI0611009A2 (pt) 2005-06-02 2010-08-10 Galaxy Biotech Llc usos de um anticorpo monoclonal (mab), e, de um anticorpo anti-hgf de neutralização
WO2007056523A2 (fr) 2005-11-08 2007-05-18 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Procedes de diagnostic et de surveillance de la progression d'un cancer
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos

Also Published As

Publication number Publication date
CN101415811B (zh) 2013-01-30
TWI417300B (zh) 2013-12-01
UA94452C2 (ru) 2011-05-10
RU2008143318A (ru) 2010-05-10
RU2461570C2 (ru) 2012-09-20
MA30382B1 (fr) 2009-05-04
JP5312315B2 (ja) 2013-10-09
US20100278815A1 (en) 2010-11-04
JP2009532378A (ja) 2009-09-10
IL194221A (en) 2015-11-30
AR059922A1 (es) 2008-05-07
ES2465668T3 (es) 2014-06-06
US8628778B2 (en) 2014-01-14
PE20080008A1 (es) 2008-02-14
NO20084539L (no) 2008-10-28
WO2007115049A3 (fr) 2008-09-04
WO2007115049A2 (fr) 2007-10-11
CA2645358C (fr) 2015-05-05
CO6140067A2 (es) 2010-03-19
KR20090013777A (ko) 2009-02-05
BRPI0709932A2 (pt) 2011-08-02
CN103172736A (zh) 2013-06-26
EP2476704A2 (fr) 2012-07-18
EP2016162B1 (fr) 2014-04-16
US20140335076A1 (en) 2014-11-13
CA2645358A1 (fr) 2007-10-11
CR10308A (es) 2008-10-27
EP2476704A3 (fr) 2012-07-25
EP2016162A4 (fr) 2009-11-11
AU2007233242A1 (en) 2007-10-11
US7632926B2 (en) 2009-12-15
HK1121489A1 (en) 2009-04-24
EP2016162A2 (fr) 2009-01-21
US20080019974A1 (en) 2008-01-24
NZ571132A (en) 2012-05-25
MX2008012619A (es) 2008-10-13
MY145042A (en) 2011-12-15
TW200808828A (en) 2008-02-16
AU2007233242B2 (en) 2012-04-26
KR101516289B1 (ko) 2015-05-07
GEP20125517B (en) 2012-05-25
CN101415811A (zh) 2009-04-22

Similar Documents

Publication Publication Date Title
ZA200807903B (en) Humanized monoclonal antibodies to hepatocyte growth factor
IL239947A (en) 21-il monoclonal antibody from human origin
HK1207974A1 (en) Monoclonal antibodies to fibroblast growth factor receptor
IL202232A0 (en) Novel rabbit antibody humanization methods and humanized rabbit antibodies
EP2349331A4 (fr) Anticorps anti-il-6 humanisés
EP2331579A4 (fr) Anticorps monoclonaux
HK1105126A1 (en) Monoclonal antibodies to progastrin
ZA200809065B (en) Humanized c-Kit antibody
ZA200809662B (en) Modified humanised anti-interleukin-18 antibodies
ZA201005348B (en) Humanized anti-c5ar antibodies
ZA201004752B (en) Humanized anti-human nkg2a monoclonal antibody
HK1138790A1 (en) Anti-sclerostin antibodies
SG10201601279SA (en) Monoclonal Antibody STRO-4
PL2195026T3 (pl) Przeciwciała przeciw sklerostynie
IL200168A0 (en) Monoclonal anti-cxcl13 antibodies
IL204835A0 (en) Humanized antibody
EP2198055A4 (fr) Anticorps pai-1 humanisés
EP2288717A4 (fr) Anticorps monoclonaux dirigés contre un facteur de croissance fibroblastique basique
ZA201004770B (en) Improved humanized anti-human x9-integrin antibody
TWI348915B (en) Anti-vegf monoclonal antibody
GB0706965D0 (en) Humanized antibody
GB0706964D0 (en) Humanized antibody
GB0706963D0 (en) Humanized antibody